Pharmaceuticals News

WATERTOWN, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...

VANCOUVER, British Columbia, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through...

PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a shared...

Kyowa Kirin Co., Ltd. announced a voluntary agreement with the U.S. government to improve access and lower medicine costs for American patients.

Company reduces the maximum aggregate payments under its royalty financing agreement from $125 million to $65 millionCompany accelerated payment of $42.6 million upfront, bringing total payments made...

Daix (France), New York City (New York, United States), August 31, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused...

Daix (France), New York City (New York, États-Unis), le 31 août, 2026 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique au stade clinique...

TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage...

PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of...

46% ORR observed among 76 evaluable patients in the ovarian cancer cohort with a median duration of response of 10.0 monthsRecent FDA interaction supports NDA submission strategy for accelerated...